WINNIPEG, Manitoba (May 13, 2015) - Kane Biotech Inc. (TSX-V:KNE), is a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms. The Company’s current focus is on the animal oral care market.
Kane Biotech is pleased to announce it has signed a joint development agreement with a global animal health company. Initial revenue from the agreement of $100,000 USD will be included in the Company’s second quarter financial statements.
“This opportunity has great potential for Kane Biotech. Industry leading partners that can provide Kane with global market access are key to the long term value of our Company” commented Mark Ahrens-Townsend, President and CEO. “I’m personally very excited and optimistic about the opportunity in front of us”.
Terms of the agreement are confidential.
Channel Expansion:
In February Kane Biotech introduced its oral care technology into the Canadian pet specialty market under the brand name bluestem™. It had previously introduced the StrixNB™ brand for the veterinary market. bluestem is a specifically formulated oral care product that contains the Company’s patent pending coactiv+™ technology.
At this date there are now 177 veterinary clinics across Canada carrying StrixNB. Kane Biotech has appointed Pan Pacific Pet for Western Canada and Pet Science for Eastern Canada as our bluestem distribution partners to service the Canadian pet specialty market. Since late Q1 50 pet specialty retailers from British Columbia to Quebec are now carrying bluestem with more pet specialty retail locations being added each month.
In follow on to the bluestem oral care water additive products, bluestem oral spray has now been added to the product family. More information on bluestem can be found at www.bluestempets.com.
Click here for more information on Kane Biotech Inc.